Disruption of the Murine Major Vault Protein (MVP/LRP) Gene Does Not Induce Hypersensitivity to Cytostatics

Mariëlle H. Mossink, Arend van Zon, Erna Fränzel-Luiten, Martijn Schoefer, Valerie A. Kickhoefer, George L. Scheffer, Rik J. Schepers, Pieter Sonneveld, and Erik A. C. Wiemer

Department of Hematology, Erasmus University Rotterdam, 3015 GE Rotterdam, the Netherlands [M. H. M., A. v. Z., E. F.-L., M. S., P. S., E. A. C. W.]; Department of Biological Chemistry and Jonsson Comprehensive Cancer Center, University of California Los Angeles, School of Medicine, Los Angeles, California 90095-1737 [V. A. K.]; and Department of Pathology, Academic Hospital “Vrije Universiteit” Amsterdam, 1081 HV Amsterdam, the Netherlands [G. L. S., R. J. S.]

ABSTRACT

Vaults are ribonucleoprotein particles with a distinct structure and a high degree of conservation between species. Although no function has been assigned to the complex yet, there is some evidence for a role of vaults in multidrug resistance. To confirm a direct relation between vaults and multidrug resistance, and to investigate other possible functions of vaults, we have generated a major vault protein (MVP/lung resistance-related protein) knockout mouse model. The MVP+/− mice are viable, healthy, and show no obvious abnormalities. We investigated the sensitivity of MVP+/− embryonic stem cells and bone marrow cells derived from the MVP-deficient mice to various cytostatic agents with different mechanisms of action. Neither the MVP+/− embryonic stem cells nor the MVP−/− bone marrow cells showed an increased sensitivity to any of the drugs examined, as compared with wild-type cells. Furthermore, the activities of the ABC-transporters P-glycoprotein, multidrug resistance-associated protein and breast cancer resistance protein were unaltered on MVP deletion in these cells. In addition, MVP wild-type and deficient mice were treated with the anthracycline doxorubicin. Both groups of mice responded similarly to the doxorubicin treatment. Our results suggest that MVP/vaults are not directly involved in the resistance to cytostatic agents.

INTRODUCTION

The 13 megadalton mammalian vault complex is the largest ribonucleoprotein particle described to date (1). Vaults are predominantly found in the cytoplasm; however, a small percentage of vaults seems to be associated with the nucleus, in particular the nuclear membrane and nuclear pore complex (2–4). Some groups have shown a partial association of vaults with cytoskeletal elements (4, 5). Although the function of vaults remains to be elucidated, the subcellular localization of the complex as well as the distinctive shape, a conserved hollow barrel-like structure with an invaginated waist and two protruding caps (6), has led to the hypothesis that vaults function in cellular transport (7) and/or nucleo-cytoplasmic transport (2–4).

Many reports point to a role for vaults in cellular defense against toxic compounds and consequently in MDR.3 Relatively high vault levels have been found in tissues that are frequently exposed to xenobiotic elements, such as epithelia of the gastrointestinal tract and lung. Furthermore, the expression of the MVP, also referred to as LRP, was associated with a non-P-gp-mediated multidrug resistant phenotype in human cancer cell lines (8–11). In addition, MVP expression closely reflected known chemoresistance characteristics in broad panels of unselected tumor cell lines and untreated clinical cancers of different histogenetic origins (8, 12). Several clinical studies indicate that expression of MVP is associated with a poor response to chemotherapy, but other studies have failed to show a correlation between MVP expression and clinical drug resistance (reviewed in Ref. 13). Direct evidence for the involvement of vaults in drug resistance was presented by Kitazono et al. (14, 15). They showed that increased levels of MVP in the colon carcinoma SW620 cells paralleled increased resistance to doxorubicin, etoposide, and Taxol. This resistance could be partly overcome by expression of MVP-specific ribozymes. However, expression of MVP, stably transfected in the ovarian carcinoma cell line A2780, leads to increased numbers of vault particles, but does not confer a drug resistance phenotype (16, 17).

Vaults consist of three proteins, a Mr 100,000 MVP, and two minor vault proteins of Mr 193,000 (VPARP) and Mr 240,000 (TEP1), as well as many copies of a small untranslated RNA (vRNA) of 88–141 bases. Interestingly, the TEP1 subunit is also associated with the telomerase complex (18, 19). Within this complex, its function is unknown, but it was shown that TEP1 binds to telomerase RNA. However, the recently generated TEP1 knockout mice do not show abnormalities in telomere length or telomerase activity (20). In these mice, vault-like particles were observed that appeared structurally intact but have a decreased density in the caps. It was found that TEP1 is capable of binding vRNA, and is responsible for the stabilization of vRNA and its binding to vaults (21). VPARP contains a functional PARP domain. Several proteins with such a domain have been identified; PARP1, the best-studied protein of this group, has been shown to play a role in base excision repair. Also, other proteins with PARP activity might be involved in DNA damage repair and genomic stability (reviewed in Ref. 22). Other than its association with the vault complex, VPARP is also located in the nucleus, which might point to an involvement in DNA damage repair as well. VPARP has been shown to ADP-ribosylate itself and MVP (23). The identification of other substrates of VPARP might give insight in the function of VPARP and/or the vault complex. However, the bulk of the vault complex is made up by the MVP. Expression of MVP in insect cells that do not express VPARP and TEP1 gives rise to vault-like particles (24), a finding that illustrates the importance of the MVP in the formation of the vault complex. Therefore, absence of MVP will most likely result in a disruption of the whole vault particle and, hence, eliminate or severely impair its function.

Here we describe the generation of a MVP-deficient mouse model. We revealed previously the genomic organization of the murine MVP gene (25), which enabled us to construct a targeting vector that was used to disrupt one allele of the MVP gene. Subsequently, we generated MVP-deficient mice that were studied extensively for any physical abnormalities. To investigate the potential role of vaults in cellular resistance to chemotherapy, several in vitro drug sensitivity assays were performed using cells and cell lines derived from the MVP knockout model. In addition, the in vivo toxicity of doxorubicin
was tested in wild-type and knockout mice to examine the effect of MVP absence on the systemic protection against chemotherapy.

MATERIALS AND METHODS

Generation of the Targeting Construct and MVP-deficient ES Cells

The MVP gene was isolated from genomic E14 DNA and mapped as described (25). By Southern blot analysis and DNA sequencing the intron-exon structure was determined. The targeting construct consisted of two genomic fragments, a 2.6-kb BstXI IIII fragment containing intron 3 and part of exon 4, and a 5-kb EcoRI-Sall fragment containing exons 8, 9, and 10. These fragments were cloned into pBS-KSII (Stratagene, La Jolla, CA). Between the two homologous arms we placed a phosphoglycerate kinase-driven neomycin cassette, in antisense direction with respect to the MVP transcription. To facilitate the screen for ES cells that underwent homologous recombination, the construct was flanked by the negative selection marker herpes simplex virus-thymidine kinase (see Fig. 1A). Before electroporation of the ES cells, the vector was linearized by digestion with NotI. The culturing and manipulation of ES cells were performed essentially as previously described (26). In short, a total of 12 × 10⁶ E14 ES cells, derived from a 129/Ola background, were mixed with 25 μg of linearized target vector and electroporated with a pulse of 117 volt and 1200 μF for 10 ms. After a 10-min incubation at room temperature, the cells were plated in 10-cm² dishes and incubated at 37°C, 5% CO₂. The following day, the cells were divided over eight dishes, and incubated in G418 and ganciclovir containing medium (300 μg/ml and 100 μg/ml, respectively). The clones surviving this selection were isolated, expanded in 24-well plates, and genotyped by Southern blot analysis of HI-digested BamHI restriction enzyme sites. Before electroporation of the ES cells, the vector was linearized by digestion with NotI. The culturing and manipulation of ES cells were performed essentially as previously described (26).

For experimental purposes, the remaining intact MVP allele was also disrupted using the same targeting construct but with the neomycin cassette replaced by a hygromycin cassette. Double-targeted ES cells were initially selected on a medium containing hygromycin only (100 μg/ml) and later examined for disruption of both MVP alleles using the 300-bp probe mentioned above.

Generation and Genotyping of MVP Knockout Mice

Chimeric mice were generated by injecting the manipulated 129/Ola-derived, MVP⁺/- ES cells into C57BL/6 blastocysts as described (26). Heterozygous offspring of the chimeric mice was used to generate MVP-deficient (MVP⁻/⁻), heterozygous (MVP⁺/-), and wild-type (MVP⁺/+)) animals. Two sets of primers were used to genotype the mice by PCR on DNA isolated from tails. One primer set specific for the wild-type allele (forward 5'-GGCTGTTCCGATCTCCTTTCTCC and reverse 5'-CAGTAGTTGTCG-AGGTCCCAAGGGTGTTAG) results in a 520-bp fragment spanning exons 6 and 7. The second primer set amplifies a 200-bp fragment of the neomycin cassette (forward 5'-TCTCAGGGAACCCGTC and reverse 5'-AGTCTGAAATTCAGAAGAG). PCR conditions were: 10 min 94°C, followed by 30 cycles of 1 min 94°C, 1 min 65°C, and 1 min 72°C, followed by 10 min at 72°C. The PCR strategy was validated by comparing the results from a Southern blot analysis with the PCR-based data (data not shown). All of the animals used in this study were of a mixed genetic background of 129/0la and C57BL/6 strains, backcrossed to C57BL/6. Littermate wild-type animals were used as controls, except in the in vivo doxorubicin experiment, where the large numbers of animals included restricted the use of controls exclusively consisting of littermates. In this experiment the groups were composed of animals from several litters matched for age and sex, and all derived from fourth-generation backcrosses with C57BL/6.

Western and Northern Blot Analysis

Tissues from MVP⁺/⁺, MVP⁺/-, and MVP⁻/- littermate animals were homogenized in a 10 mM sodium phosphate buffer (pH 7.4) containing 0.25% (v/v) Triton X-100 and proteinase inhibitors, using an Ultra-Turrax T25 (IKA-Labortechnik). The tissue lysates were spun briefly to pellet insoluble material. Protein concentrations were determined by the bicinchoninic acid method (Pierce, Rockford, IL). MVP was detected using a polyclonal antibody raised against human MVP (9) and the enhanced chemiluminescence detection system (Amersham-Pharmacia, Uppsala, Sweden).

Total RNA was purified from MVP⁺/⁺, MVP⁺/-, and MVP⁻/- littermate animals using RNAzol (Campro Scientific, Berlin, Germany) following the recommendations of the manufacturer. Ten μg of total RNA was subjected to formaldehyde-agarose gel electrophoresis as described (27). Subsequently the size-fractionated RNA was blotted onto Hybond-N* filters (Amersham, Little Chalfont, United Kingdom). ULTRAhyb (Ambion, Austin, TX) was used as blocking and hybridization mix according to the recommendations of the manufacturer. The blot was probed overnight with an in vitro transcribed antisense [³²P]-labeled MVP RNA probe, at 68°C, and subsequently washed for 2 × 5 min in 2 × SSC, 0.1% SDS and 2 × 15 min in 0.1 × SSC, 0.1% SDS at 68°C. As a loading control, afterward the same blot was probed with a radiolabeled 18 S rRNA oligonucleotide probe (5'-CTTTGCTATCGTCG-CTTGGCGCCGGTCC).

Vault Purification and Analysis

Vaults were purified from mouse livers as described previously (6), using a protocol adapted to the limited quantities and size of the mouse livers (21). Electron microscopy of uranyl acetate-stained vaults was carried out as described (28).

Isolation of Immature Bone Marrow Cells

Femurs and tibia were isolated from MVP⁺/⁺ and MVP⁻/- littermates. The bones were cleaned and crushed in a sterile mortar to extract the cells using HBSS with 5% FCS, penicillin (100 units/ml), and streptomycin (100 mg/ml). The cells were filtered through a 100-mm cell strainer (Becton Dickinson, Franklin Lakes, NJ) and spun down at 500 × g for 10 min. The cell pellet was resuspended in 50 ml of HBSS, and incubated at 37°C and 5% CO₂ for 60 min. To separate the immature proliferative cells from the more mature bone cells, the cells were filtered through a 100-mm cell strainer (Becton Dickinson, Franklin Lakes, NJ) and spun down at 500 × g for 10 min. The cell pellet was resuspended in 50 ml of HBSS, and incubated at 37°C and 5% CO₂ for 60 min. To separate the immature proliferative cells from the more mature bone
marrow cells, the cells were harvested and resuspended in 300 ml of Ca²⁺/Mg²⁺-free PBS, and mixed with 2.7 ml of a 55% Percoll (Amersham-Pharmanual) solution. This mixture was loaded on a Percoll gradient, consisting of 3 ml of 85%, 2 ml of 62%, and 2 ml of 55% Percoll in Ca²⁺/Mg²⁺-free HBSS. The gradient was centrifuged for 30 min at 1650 × g using slow acceleration and no brakes. The upper fraction, containing the most immature cells, was collected. To induce proliferation, the cells were prestimulated in Cellgro medium (Boehringer, Heidelberg, Germany) containing 10 ng/ml thrombopoietin (Genentech, South San Francisco, CA), 10 ng/ml granulocyte macrophage colony-stimulating factor (R&D, Minneapolis, MN), 10 ng/ml interleukin 3 (R&D), 100 ng/ml stem cell factor (Amgen, Thousand Oaks, CA), and 50 ng/ml FLT3 (Immunex, Seattle, WA). After 2 days the cells were harvested and used in proliferation assays. During the proliferation assays the cells were cultured in medium containing the growth factors mentioned above.

Functional Tests for P-gp, MRP1, and BCRP

The activities of P-gp, MRP1, and BCRP were monitored by fluorescence-activated cell sorter analysis. Three × 10⁶ wild-type and knockout ES cells or immature bone marrow cells were incubated in DMEM with or without 2 mM of the P-gp inhibitor PSC 833 (Novartis Pharma), 100 μM of the MRP1 inhibitor MK571 (Alexis, Lausen, Switzerland), or with 200 nM of the BCRP modulator Ko143 (29). After a 30–60 min incubation at 37°C, 5% CO₂, 200 ng/ml Rhodamine-123 (Sigma-Aldrich), 100 ng DCFDA (Sigma-Aldrich), or 100 nM BODIPY-prazosin (Molecular Probes Inc., Eugene, OR), substrates for P-gp, MRP1, or BCRP, respectively, was added. The cells were incubated with the substrates for an additional 75 min, after which the cells were mixed with 2 ml of ice-cold PBS supplemented with 0.1% sodium azide and spun at 100,000 × g. After analyzing the cells by fluorescence-activated cell sorter, 8 μl of 5 mM TOPRO-3 (Molecular Probes) was added. 8226S and the P-gp-overexpressing derivative 8226D6 (30), GLC4 and the drug-resistant derivative expressing MRP1, and vaults GLC4-ADR (31) and MCF-7 and the drug-resistant, BCRP-overexpressing cell line MCF-7 AdVp3000 (32) were included as positive and negative controls for P-gp, MRP1, and BCRP function, respectively.

Analysis of Drug Sensitivity

**Cell Survival Assay.** The sensitivity to anticancer agents was tested in *MVP⁺⁺* and *MVP⁻⁻* ES cells using a MTt microtiter plate assay (33). In brief, on day 1, 3000 cells were seeded in 50 μl medium/well on gelatin-coated, flat-bottomed 96-well plates. After an incubation of 6 h at 37°C, 5% CO₂, 200 μl of a 5 mg/ml MTT solution in 0.9% NaCl was added in each well, and the incubation continued for an additional 6 h at 37°C, 5% CO₂. The formazan crystals produced by viable cells were resuspended by adding 100 μl/well of acidified isopropanol, after which the absorbance at 562 nm was measured on a plate reader. At least 12 different drug concentrations were used to determine IC₅₀ values.

**Cell Proliferation Assay.** Proliferation of bone marrow cells from *MVP⁺⁺* and *MVP⁻⁻* littermate mice was tested in a [³H]thymidine incorporation assay. For this purpose, immature bone marrow cells, isolated by a Percoll gradient and prestimulated for 48 h, were seeded at a density of 20,000 cells/well in a microtiter plate in 100 μl of medium containing growth factors and incubated at 37°C, 5% CO₂. Drugs were added 24 h later in various concentrations, and the cells were incubated for an additional 8 h. Then [³H]thymidine (25 μCi in 25 μl medium) was added to each well, and the cells were incubated overnight. Cells were transferred to a glass fiber filter using a filtrate 196 cell harvester (Packard Bioscience, Groningen, The Netherlands), and the radioactivity on the filters was determined by a topcount microplate scintillation counter (Packard Bioscience).

**In Vivo Toxicity of Doxorubicin.** Ten or 15 mg doxorubicin/kg body-weight was administered to *MVP* knockout animals, and age- and sex-matched wild-type animals by i.v. injection in the tail. The animals were examined daily for signs of discomfort and illnes. Body weights were determined daily, and blood cell counts were performed on days 3 and 8 after injection. At day 5 after injection, the animals that received the 10 mg/kg doxorubicin dose and PBS injected controls were sacrificed and examined thoroughly for histopathologic abnormalities using standard protocols.

**RESULTS**

**MVP-deficient Mice Are Viable and Appear Normal.** ES cell clones surviving the selection medium were genotyped by digestion with *Bam*HI followed by Southern blot analysis. This resulted in a 9.8-kb and a 3.2-kb hybridizing fragment for the wild-type and recombinant allele, respectively (Fig. 1B). A probe at the 5’ end of the construct was used to confirm the disruption of the *MVP* allele. The presence of additional integrations was excluded by using a probe based on the neomycin cassette (results not shown). Before the *MVP⁺⁻* ES cells were injected into blastocysts, the number of chromosomes present in metaphase spreads was counted to verify the karyotype was stable.

Chimeric animals, resulting from blastocyst injection, were backcrossed to C57BL/6 mice to obtain heterozygous animals. These heterozygous mice were intercrossed to produce *MVP⁺⁺* and *MVP⁻⁻* littersmates. The genotype of the animals was determined by Southern blot analysis and/or PCR on tail DNA (compare Fig. 1B). The disruption of *MVP* was confirmed at RNA and protein level. A Northern blot analysis on total RNA isolated from liver from wild-type, heterozygous, and *MVP*-deficient animals demonstrated that no *MVP* transcripts were detectable in the knockout tissue. Although the loading was not completely equal, judged from the 18S rRNA signal, a decreased signal was found in the heterozygous tissue when compared with the normal tissue (Fig. 2A). On Western blot, the knockout tissues contained no detectable MVP, and the heterozygous tissues showed intermediate levels of protein expression (Fig. 2B). Similar results were observed with other organs (data not shown).

To verify that the vault particle is indeed disrupted on the loss of MVP, we biochemically fractionated wild-type and *MVP* knockout mouse livers to purify vaults. In the final purification step, the vaults were purified over a single cesium chloride gradient. Vaults were recovered from gradient fractions by dilution and pelleting at 100,000 × g, and analyzed by electron microscopy (Fig. 2C). The typical barrel-shaped vault particles were clearly present in the wild-type liver fractions but could not be detected in the corresponding fractions obtained from *MVP* knockout livers. This indicates that MVP cannot be substituted for by another protein, which is in agreement with our previous findings that the murine genome contains a single MVP gene (25).

The MVP knockout mice appeared viable, were born at Mendelian ratios, bred normally, and did not show clear physical abnormalities up to 16 months of age. Animals of different ages were histologically examined, with special attention to tissues that normally express relatively high levels of MVP/vaults (*i.e.*, lung, liver, and gastrointestinal tract). No morphocical differences were observed between knockout and wild-type littersmates (data not shown). Also, no differences were observed in bone marrow and peripheral blood cell counts, and in serum levels of glucose, blood urea, cholesterol, and creatine (results not shown).

**Drug Sensitivity in MVP-deficient Cells.** A correlation between vault expression and drug resistance has been shown in cell lines as well as for primary human tumors. To examine whether vaults influence the cellular defense against drugs, we tested the sensitivity of ES cells and immature bone marrow cells to various cytostatic agents. Both ES and immature bone marrow cells were shown to express MVP/vaults, whereas no MVP could be detected in *MVP⁺⁻* ES and bone marrow cells derived from *MVP⁺⁻* mice (Fig. 3). The survival of *MVP⁺⁻* ES cells in response to increasing concentrations of cytostatic drugs was compared with the survival of the parental *MVP⁺⁺* ES cells in a MTT assay. To determine the drug concentration IC₅₀ value, 12 different concentrations of each drug were tested. Although a broad range of drugs, exerting toxicity in different man-

Downloaded from cancerres.aacrjournals.org on April 12, 2017. © 2002 American Association for Cancer Research.
VAULTS AND DRUG RESISTANCE

concentrations at which the proliferation is decreased by 50% are listed in Table 2. In all of the cases, the inhibition of cell proliferation induced by the cytostatics appears unaltered in MVP-deficient cells.

To test whether the absence of MVP results in altered expression of other multidrug resistance-related proteins such as P-gp, MRP1, and BCRP, the activities of these membrane pumps were examined in wild-type and knockout ES cell lines and bone marrow cells. For this purpose, we measured the intracellular retention of fluorescent substrates in the presence or absence of P-gp, MRP1, and BCRP modulators by flow cytometry. The ratio of substrate retained in the cell in the presence and absence of their modulators is a measure of the activity of these membrane pumps. Table 3 summarizes the activities of the three proteins on ES cells and immature bone marrow cells. Both ES cells and bone marrow cells appear to exhibit a low activity of P-gp and BCRP, whereas addition of the MRP1 modulator MK571 clearly increased the intracellular amount of fluorescent substrate, indicating that MRP1 is functionally present on the surfaces of these cells (Fig. 4). However, the absence of MVP does not lead to an increased activity in any of the MDR-related proteins tested. To investigate whether the inhibition of MRP1 has more severe consequences for the MVP knockout cells than for the MVP wild-type cells, the sensitivity to doxorubicin and etoposide in the presence of the MRP1 modulator MK571 was tested in a MTT assay. Doxorubicin and etoposide were chosen because these agents are known substrates of P-gp, BCRP, and MRP1.

Table 1 In vitro cytotoxicity of several cytostatics in MVP+/+ and MVP−/− ES cells

<table>
<thead>
<tr>
<th>Agent</th>
<th>MVP+/+ ES cells</th>
<th>MVP−/− ES cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>7.28 ± 1.0</td>
<td>6.15 ± 0.77</td>
</tr>
<tr>
<td>Doxorubicin + 50 µM MK571</td>
<td>3.6 ± 1.0</td>
<td>4.3 ± 0.5</td>
</tr>
<tr>
<td>Etoposide</td>
<td>2.38 ± 0.08</td>
<td>2.0 ± 0.08</td>
</tr>
<tr>
<td>Etoposide + 50 µM MK571</td>
<td>1.0 ± 0.08</td>
<td>0.9 ± 0.2</td>
</tr>
<tr>
<td>Vinristine</td>
<td>0.86 ± 0.2</td>
<td>0.83 ± 0.05</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>11.4 ± 0.58</td>
<td>12.9 ± 2.3</td>
</tr>
<tr>
<td>Hsfamidam</td>
<td>466 ± 103 × 10^3</td>
<td>471 ± 103 × 10^3</td>
</tr>
<tr>
<td>Mitoxantone</td>
<td>0.53 ± 0.08</td>
<td>0.7 ± 0.2</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>10.05 ± 0.8</td>
<td>10.35 ± 1.1</td>
</tr>
<tr>
<td>Taxotere</td>
<td>0.38 ± 0.1</td>
<td>0.30 ± 0.023</td>
</tr>
<tr>
<td>Cisplatinum</td>
<td>198 ± 37</td>
<td>228 ± 52</td>
</tr>
<tr>
<td>Melphalan</td>
<td>244 ± 71</td>
<td>299 ± 34</td>
</tr>
<tr>
<td>Cytosine arabinoside</td>
<td>151 ± 36</td>
<td>244 ± 88</td>
</tr>
<tr>
<td>Dexamethason</td>
<td>25 ± 103 × 10^3</td>
<td>35 ± 103 × 1330</td>
</tr>
</tbody>
</table>

Table 2 Inhibition of proliferation of MVP+/+ and MVP−/− bone marrow cells in response to several cytostatic agents

<table>
<thead>
<tr>
<th>Drug concentration (µg/ml)</th>
<th>MVP+/+ bone marrow cells</th>
<th>MVP−/− bone marrow cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>0.131 ± 0.026</td>
<td>0.119 ± 0.027</td>
</tr>
<tr>
<td>Etoposide</td>
<td>2.73 ± 1.47</td>
<td>2.84 ± 1.47</td>
</tr>
<tr>
<td>Vinristine</td>
<td>0.047 ± 0.008</td>
<td>0.055 ± 0.004</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>0.046 ± 0.006</td>
<td>0.039 ± 0.0015</td>
</tr>
<tr>
<td>Hsfamidam</td>
<td>2423 ± 270</td>
<td>1991 ± 514</td>
</tr>
<tr>
<td>Mitoxantone</td>
<td>0.0073 ± 0.0016</td>
<td>0.0081 ± 0.002</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>0.029 ± 0.011</td>
<td>0.0183 ± 0.001</td>
</tr>
<tr>
<td>Taxotere</td>
<td>0.0058 ± 0.0006</td>
<td>0.0054 ± 0.0004</td>
</tr>
<tr>
<td>Cisplatinum</td>
<td>7.06 ± 2.27</td>
<td>6.23 ± 2.48</td>
</tr>
<tr>
<td>Melphalan</td>
<td>5.06 ± 1.19</td>
<td>3.93 ± 1.53</td>
</tr>
<tr>
<td>Cytosine arabinoside</td>
<td>0.11 ± 0.02</td>
<td>0.11 ± 0.003</td>
</tr>
<tr>
<td>Dexamethason</td>
<td>322 ± 36</td>
<td>326 ± 44</td>
</tr>
</tbody>
</table>
of MRP1. Although the IC$_{50}$ values of both doxorubicin and etoposide were clearly reduced by adding MRP1 inhibitor (Table 1), this effect was not found to be more pronounced in the MVP-deficient cells.

**Toxicity of Doxorubicin in Vivo.** Although the disruption of the MVP gene did not result in an altered sensitivity to drugs in bone marrow and ES cells, it is possible that MVP/vaults play a role in the protection of a specific organ. Such an observation was reported for the P-gp-deficient mice, in which absence of P-gp in the blood-brain barrier led to accumulation of ivermectin in the brain, resulting in a 100-fold increased sensitivity level to this agent (34). We tested the in vivo toxicity of doxorubicin in MVP knockout mice, because the relation between drug resistance and MVP expression was most obvious for anthracyclines (14, 15). We examined the general appearance, weight loss, and blood cell numbers of 21 wild-type and 23 knockout mice treated with a single i.v. doxorubicin injection of 15 mg/kg bodyweight. The MVP-deficient animals did not show increased symptoms of illness and discomfort when compared with wild-type control animals. The number of WBCs was slightly decreased 3 days after injection in both groups when compared with noninjected animals, but had recovered in both wild-type and knockout mice on day 8 (data not shown). The effects of the doxorubicin treatment on the bodyweights are presented in Fig. 5. Both MVP$^{+/+}$ and MVP$^{-/-}$ animals showed loss of weight during the first days after injection, but the average weight loss was similar in both groups, and all of the animals were able to stabilize and started to recover their weights. Furthermore, the damage to organs after injection of 10 mg doxorubicin/kg bodyweight was investigated extensively, with special attention to organs that normally exhibit a high expression of MVP. Effects of the doxorubicin treatment, such as hydropy in the liver and the disruption of the morphology of the villi in the ileum, were visible in both knockout and wild-type organs (5 wild-type versus 5 knockout animals), but the levels of the induced tissue damage were similar (data not shown).

**DISCUSSION**

We have successfully generated a MVP knockout mouse. The MVP mRNA and protein are undetectable in the tissues of the knockout animals and severely reduced in heterozygous animals. Moreover, vault particles could no longer be detected in the MVP knockout tissues.

Both the high degree of evolutionary conservation and the complex structure of vault particles, as well as its broad distribution in tissues suggest an important function in cellular processes. Surprisingly, the MVP knockout animals do not show any obvious abnormalities, breed normally, and appear healthy. Apparently, vaults do not play an essential role in the development of mice and in cellular processes in a normal healthy environment. However, vaults could be involved in a strategic mechanism needed for survival after induction of cellular

---

**Table 3 Functional expression of P-gp, MRP1, and BCRP in MVP$^{+/+}$ and MVP$^{-/-}$ cells**

<table>
<thead>
<tr>
<th>Bone Marrow</th>
<th>ES cells</th>
<th>MVP$^{+/+}$</th>
<th>MVP$^{-/-}$</th>
<th>MVP$^{+/+}$</th>
<th>MVP$^{-/-}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp</td>
<td>1.45</td>
<td>1.51</td>
<td>1.21</td>
<td>0.95</td>
<td></td>
</tr>
<tr>
<td>MRP1</td>
<td>10.41</td>
<td>10.48</td>
<td>7.5</td>
<td>8.8</td>
<td></td>
</tr>
<tr>
<td>BCRP</td>
<td>1.34</td>
<td>1.09</td>
<td>1.18</td>
<td>1.15</td>
<td></td>
</tr>
</tbody>
</table>

---

**Fig. 4.** Functional expression of MDR-related proteins in wild-type and MVP knockout cells. The activities of P-gp, MRP1, and BCRP are presented as the intracellular amounts of Rhodamine-123 (P-gp substrate), DCFDA (MRP1 substrate), or BODIPY-prazosin (BCRP substrate) in wild-type (WT) and MVP-deficient (KO) ES cells in presence (gray plot) or absence (black plot) of the modulators PSC 833, MK571, and Ko143.
stress or damage. Because the cellular defense against cytotoxic agents may partly rely on vaults, as was suggested in several clinical studies and experiments using MDR cell lines, we have examined a potential function of vaults in multidrug resistance. To this purpose, two different cell types derived from the MVP knockout model were tested in two different assays. Firstly, the survival of MVP<sup>+/+</sup> and MVP<sup>−/−</sup> ES cells, when exposed to different concentrations of cyto-
statics, was examined in a MTT assay. Similar experiments have been performed in MRP1 deficient ES cells by Lorico et al. (35), who observed that disruption of MRP1, a MDR-related membrane trans-
port protein, leads to hypersensitivity to etoposide and temiposide and, to a lesser extent to doxorubicin. Decreased IC<sub>50</sub> values of up to 4-fold were reported. In our experiments, no significant difference in IC<sub>50</sub> values and no difference in the survival curves of MVP-deficient and wild-type ES cells were observed. Secondly, the effects of cytostatic agents on the proliferative capacity of immature bone marrow cells isolated from knockout and wild-type littermate animals were exam-
ined in a [3H]thymidine incorporation assay. The inhibition of prolif-
eration in response to all of the administered drugs was similar in wild-type and MVP-deficient cells. Finally, although more extensive research using several cytotoxic agents at different concentrations should be performed to determine the in vivo sensitivity of the MVP knockout mice, the systemic protection to doxorubicin seems unal-
tered in MVP-deficient mice as compared with the wild-type control mice. Siva et al. (17) suggested that vaults may be necessary, although not sufficient for drug resistance. The data presented in this study confirm these findings, and even suggest that MVP and intact vaults are not necessary for the resistance to a broad range of anticancer drugs.

In contrast, in a number of cell line models, MVP expression has been found to correlate with resistance to several cytostatic agents. A clear relation between MVP expression levels and resistance to doxo-
rubicin, etoposide, Taxol, and vincristine was reported by Kitazono et al. (14, 15). Colon cancer SW-620 cells with induced MVP expression were 6-fold more resistant to doxorubicin, 9-fold to etoposide, 8-fold to Taxol, and 2-fold to vincristine, as determined by a MTT assay. When MVP transcript levels were decreased by the expression of MRP-specific ribozymes, the cells lost the acquired resistance. A mechanism for the action of MVP/vaults proposed by the authors is the efflux of doxorubicin from the nucleus. However, because not all of the drugs investigated in their study have nuclear targets, this only explains part of the acquired resistance of the SW-620 cells. The results of these studies also imply that by losing MVP, cells become more susceptible to doxorubicin, etoposide, and Taxol. However, the MVP-deficient ES and bone marrow cells used in our study were not more susceptible to these cytostatic agents or to any other agent tested.

A possible explanation for the unexpected lack of a drug-sensitive phenotype in the MVP-deficient mice is that vaults only contribute moderately to drug resistance and that the absence of MVP is compensated for by other MDR proteins, like ABC-transporters such as P-gp, MRP family members, or BCRP. However, in the MVP-deficient cell systems used in this study, no increase of activity of P-gp, MRP1, and BCRP was observed. A functional assay showed a consider-
able activity of MRP1 in both ES cells and bone marrow cells, but this activity did not change after disruption of MVP. Addition of a MRP1 inhibitor indeed increased the susceptibility of ES cells for the MRP1 substrates, doxorubicin and etoposide, but the effects were identical in MVP wild-type and deficient cells. Hence, it is not likely that the effects of the disruption of MVP are compensated for by P-gp, MRP1, or BCRP. However, it cannot be excluded that other ABC-
transporters or unknown mechanisms of drug resistance become up-
regulated on disruption of MVP. Furthermore, our experiments did not include long-term exposure of cells to low doses of cytostatic agents.

Although a direct involvement of vaults in MDR cannot be demon-
strated in the MVP knockout mouse model, vaults might still be involved in the protection against chronic exposure to drugs. On the other hand, the up-regulation of MVP that has been described in both in vitro and clinical studies might be a response to cyto
tastics but not directly related to the resistance to these agents. Vaults may be involved in other cellular processes that also become activated on exposure to toxic agents, such as apoptosis and/or a general stress response. In addition, some evidence for a role of vaults in cellular differentiation was given by Schroeijers et al. (36). The observed up-regulation of vaults during the development of dendritic cells and the impaired function of dendritic cells treated with antibodies against MVP suggest that vaults play a role in the development, maturation, and functioning of dendritic cells. We are currently investigating the development and antigen-presenting capacity of dendritic cells de-

mitted on April 12, 2017. © 2002 American Association for Cancer Research.


Disruption of the Murine Major Vault Protein (MVP/LRP) Gene Does Not Induce Hypersensitivity to Cytostatics


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/62/24/7298

Cited articles
This article cites 34 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/62/24/7298.full.html#ref-list-1

Citing articles
This article has been cited by 16 HighWire-hosted articles. Access the articles at:
/content/62/24/7298.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.